Valproate in the treatment of rapid-cycling bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 8, Issue 4, 1988, Pages 275-279

  Susan, L Mcelroy ^a,b   Paul, E Keck ^a,b   Harrison, G Pope ^a,b   James, I Hudson ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; CLINICAL ARTICLE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS;

ADULT; BIPOLAR DISORDER; CASE REPORT; FEMALE; HUMAN; MALE; MIDDLE AGE; SCHIZOTYPAL PERSONALITY DISORDER; VALPROIC ACID;

EID: 0023810887     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229–33.
2. Dunner DL, Patrick V, Fieve RR. Rapid-cycling manic depressive patients. Compr Psychiatry 1977;18:561–6.
3. Roy-Byrne PP, Joffe RT, Uhde TW, et al. Approaches to the evaluation and treatment of rapid-cycling affective illness. Br J Psychiatry 1984;145:543–50.
4. Jones BD, Steinberg S, Chouinard G. Fastcycling bipolar disorder induced by withdrawal from long-term treatment with tricyclic antidepressant. Am J Psychiatry 1984;141:108–9.
5. McElroy SL, Keck PE Jr, Pope HG Jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7: 16–24.
6. McElroy SL, Pope HG Jr, Keck PE Jr, et al. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatr Psychobiol 1988;3:81–5.
7. Squillace K, Post RM, Savard R, et al. Life charting of the longitudinal course of recurrent affective illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:38–59.
8. Herridge PL, Pope HG Jr. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985;5:229–30.
9. Berrettini WH, Post RM. GABA in affective illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:673–85.
10. Lloyd KG, Morselli PL. Psychopharmacology of GABAergic drugs. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:183–95.
11. Chouinard G, Young SN, Annable L. Antimanic effects of clonazepam. Biol Psychiatry 1983;18:451–66.
12. Post RM, Stoddard FJ, Gillin JC, et al. Alterations in motor activity, sleep, and biochemistry in a cycling manicdepressive patient. Arch Gen Psychiatry 1977;43:470–7.
13. Ostrow D, Halaris A, Dysken M, et al. State dependence of noradrenergic activity in a rapidly cycling bipolar patient. J Clin Psychiatry 1984;45:306–9.
14. Brennan MJW, Sandyk R, Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okuma T, Müller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:56–65.
15. Pérez de al Mora M, Possani LD, Tapia R, et al. Demonstration of central gamma-aminobutyrate-containing nerve terminals by means of antibodies against glutamate decarboxy lase. Neuroscience 1981;6:875–95.
16. Rimmer E, Richens A. An update on sodium valproate. Pharmacotherapy 1985;5:181–4.
17. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379–85.